<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155713</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2116</org_study_id>
    <nct_id>NCT01155713</nct_id>
  </id_info>
  <brief_title>Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and
      the effect of food on the bioavailability of TKI258, in adult patients with advanced solid
      tumor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the relative bioavailability of the final market image form of TKI258 (monohydrate tablets) as compared to the clinical service form of TKI258 (anhydrate capsules)</measure>
    <time_frame>relative bioavailability (9 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the effect of food on the bioavailability of TKI258</measure>
    <time_frame>food effect (22 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety and tolerability of TKI258, including acute and chronic toxicities.</measure>
    <time_frame>Up to 28 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary evidence of anti-tumor activity of TKI258 in patients with advanced solid tumors.</measure>
    <time_frame>Every 8 weeks until progression of disease</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Neoplasm</condition>
  <condition>Cancer</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Arm 1 - TKI258 - bioavailability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI258 - food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <arm_group_label>Arm 1 - TKI258 - bioavailability</arm_group_label>
    <arm_group_label>TKI258 - food effect</arm_group_label>
    <other_name>Dovitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an advanced solid tumor which has progressed despite standard therapy,
             or for which no standard therapy exists

          -  World Health Organization (WHO) performance status â‰¤ 2

          -  Patient must meet protocol-specified laboratory values

        Exclusion Criteria:

          -  Patients with brain cancer

          -  Patients who have concurrent severe and/or uncontrolled medical conditions which could
             compromise participation in the study

          -  Patients who have not recovered from previous anti-cancer therapies

          -  Female patients who are pregnant, breast feeding, or not willing to use an effective
             method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Sarah Cannon Research Instit</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumors</keyword>
  <keyword>Administration, oral</keyword>
  <keyword>Capsules</keyword>
  <keyword>CHIR258, CHIR-258, CHIR 258, TKI258, TKI-258, TKI 258,</keyword>
  <keyword>Bioavailability,</keyword>
  <keyword>Food</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

